ArticleArchives of medical science : AMS2017
Down-regulation of microRNA-182 and microRNA-183 predicts progression of osteosarcoma.
Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Exosomal miR-182-5p from breast cancer cells reprogram tumor-associated macrophages and promote triple-negative breast cancer progression by targeting Notch1 in macrophages.Archives of medical science : AMS · 2025Article
- The miR-183 Cluster: Biogenesis, Functions, and Cell Communication via Exosomes in Cancer.Cells · 2023Review
- Clinical value of microRNA-19a-3p and microRNA-99a-5p in bladder cancer.Archives of medical science : AMS · 2023Article
- MiR-183-5p Promotes Tumor Progression of Osteosarcoma and Predicts Poor Prognosis in Patients.Cancer management and research · 2021Article
- Knockdown of microRNA-130b improves doxorubicin sensitivity in bladder urothelial carcinoma by negatively regulating cylindromatosis expression.Archives of medical science : AMS · 2021Article
- MicroRNA-182-5p Modulates Oral Squamous Cell Carcinoma Migration and Invasion Via Targeting MTSS1 Gene.Pathology oncology research : POR · 2020Article
- MicroRNAs signatures, bioinformatics analysis of miRNAs, miRNA mimics and antagonists, and miRNA therapeutics in osteosarcoma.Cancer cell international · 2020Review
- Long non-coding RNA DANCR promotes cervical cancer growth via activation of the Wnt/β-catenin signaling pathway.Cancer cell international · 2020Article
- Association of High miR-182 Levels with Low-Risk Prostate Cancer.The American journal of pathology · 2019Article
- miR-363-3p Inhibits Osteosarcoma Cell Proliferation and Invasion via Targeting SOX4.Oncology research · 2019Article
- Novel molecular insights and new therapeutic strategies in osteosarcoma.Cancer cell international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this study was to investigate the expression levels of microRNA-182 and microRNA-183 and their association with clinicopathological features in patients with osteosarcoma. MATERIAL AND
methodsTotal RNA was purified from samples and noncancerous bone tissues and then quantitative real-time polymerase chain reaction was applied to evaluate the expression levels of microRNAs, and their relationship with clinicopathological features and survival in osteosarcoma patients.
resultsOur findings showed that expression of MiR-182 was clearly lower in osteosarcoma bone tissue (mean ± SD: 2.84 ±.07) compared with noncancerous bone tissues (6.23 ±1.72,
conclusionsThese findings suggest that MiR-182 and MiR-183 may be associated with progression and metastasis of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.